On May 26, 2023 PharmaMar (MSE:PHM) has reported that it will present, together with its partners, seven new abstracts from various clinical studies with Zepzelca (lurbinectedin) and Yondelis (trabectedin) at the annual meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) (ASCO, American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)), which will be held from June 2 to 6, 2023 virtually and in person in Chicago, United States (Press release, PharmaMar, MAY 26, 2023, View Source [SID1234632088]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Among the studies that will be presented during the congress, two oral presentations with two PharmaMar compounds stand out. With the abstract titled: " Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS)", Dr. Gregory Cote , a medical oncologist at Massachusetts General Hospital, will present updated efficacy and tolerability data of the combination of lurbinectedin with doxorubicin, from the phase 1B introduction of soft tissue sarcoma to a phase II randomized trial in leiomyosarcoma (LMS).
For his part, Dr. Peter Reichardt, Chief Medical Officer of the HELIOS Klinikum Berlin-Buch Interdisciplinary Oncology Clinic, will present the abstract entitled: "Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc)", in which he will present data on the efficacy and safety of trabectedin plus nivolumab as second-line treatment of patients with metastatic or inoperable soft tissue sarcoma previously treated with anthracyclines. The study confirms the activity of trabectedin plus nivolumab, particularly in patients with lipo or leiomyosarcomas, suggesting a synergistic activity. Furthermore, the safety of trabectedin and nivolumab was consistent with the safety profiles of each drug separately, with no new findings relevant to the combination.
All ASCO (Free ASCO Whitepaper) abstracts are available upon request to registered participants for 180 days from May 26, 2023: View Source
Studies featured at ASCO (Free ASCO Whitepaper) 2023
PRODUCT TITLE PRIMARY AUTHOR ABSTRACT
Zepzelca (lurbinectedina) Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS) Gregory Cote ABSTRACT: 11507 SESSION TYPE: Oral Abstract Session S100a DATE: June 5, 2023 11:30 – 14:30 GMT-5
Zepzelca (lurbinectedina) Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC Sophie Cousin ABSTRACT: 8591 SESSION TYPE: Poster Session POSTER: 218 DATE: June 4, 2023 8:00 – 11:00 GMT-5
Zepzelca (lurbinectedina) A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator’s choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial) Benjamin Besse ABSTRACT: TPS8613 SESSION TYPE: Poster Session POSTER: 233a DATE: June 4, 2023 8:00 – 11:00 GMT-5
Zepzelca (lurbinectedina) IFCT-2105 lurbiclin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU) Nicolas Girard ABSTRACT: 8584 SESSION TYPE: Poster Session POSTER: 211 DATE: June 4, 2023 8:00 – 11:00 GMT-5
Yondelis (trabectedin) Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc) Peter Reichardt ABSTRACT: 11500 SESSION TYPE: Oral Abstract Session S100a DATE: June 5, 2023 11:30 – 14:30 GMT-5
Yondelis (trabectedin) SARC037: Results of phase I study of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in relapsed/refractory Ewing sarcoma (ES) Patrick Grohar ABSTRACT: 11519 SESSION TYPE: Poster Discussion Session POSTER: 453 DATE: June 3, 2023 16:30 – 18:00 GMT-5
Yondelis (trabectedin) Trabectedin (T) versus adriamycin plus dacarbazine (A-DA) in advanced solitary fibrous tumor (SFT): Results from a phase II randomised clinical study (STRADA) Silvia Stacchiotti ABSTRACT: 11571 SESSION TYPE: Poster Session POSTER: 505 DATE: June, 2023 13:15 – 16:15 GMT-5